Natural Killer Cell-Mediated Shedding of ULBP2
Explore this paper's citation graph
Summary
It is shown, for the first time, that human tumor cells lost their surface expression of ULBP2, but not ULBP1 and ULBP3, during NK cell-mediated cytolysis, illustrating a regulation of NK cell effector functions through cy tolysis-induced NKG2D ligand shedding.
- Type
- article
- Published
- 2014-03-10
- Cited by
- 15
- References
- 29
- Access
- Open access
- OpenAlex
- https://openalex.org/W1979302439
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:15770414
Keywords
NKG2D, Cytolysis, Cell biology, Cytotoxicity, Cell
References
- Effect of NKG2D ligand expression on host immune responses
- Costimulation of CD8alphabeta T cells by NKG2D via engagement by MIC induced on virus-infected cells.
- Natural killer cells in human autoimmune diseases
- Proteomic profiling of exosomes: Current perspectives
- Apoptosis-inducing Agents Cause Rapid Shedding of Tumor Necrosis Factor Receptor 1 (TNFR1)
- Natural killer cells in human autoimmune disorders
- Roles of the NKG2D immunoreceptor and its ligands
- Apoptosis is a natural stimulus of IL6R shedding and contributes to the proinflammatory trans-signaling function of neutrophils.
- The topoisomerase inhibitors camptothecin and etoposide induce a CD95-independent apoptosis of activated peripheral lymphocytes
- NKG2D-deficient mice are defective in tumor surveillance in models of spontaneous malignancy.
- Clinical significance of the NKG2D ligands, MICA/B and ULBP2 in ovarian cancer: high expression of ULBP2 is an indicator of poor prognosis
- Diagnostic and prognostic impact of serum‐soluble UL16‐binding protein 2 in lung cancer patients
- The prognostic significance of soluble NKG2D ligands in B-cell chronic lymphocytic leukemia
- Ectopic expression of retinoic acid early inducible-1 gene (RAE-1) permits natural killer cell-mediated rejection of a MHC class I-bearing tumor in vivo
- Functional significance of the perforin/granzyme cell death pathway
- Antiapoptotic mechanism of HIV protease inhibitors: preventing mitochondrial transmembrane potential loss.
- Proteolysis of the urokinase-type plasminogen activator receptor by metalloproteinase-12: implication for angiogenesis in fibrin matrices.
- Regulatory NK cells in autoimmune disease.
- High Levels of Exosomes Expressing CD63 and Caveolin-1 in Plasma of Melanoma Patients
- ULBPs, novel MHC class I-related molecules, bind to CMV glycoprotein UL16 and stimulate NK cytotoxicity through the NKG2D receptor.
Cited by
- An optimized procedure for exosome isolation and analysis using serum samples: Application to cancer biomarker discovery.
- NK cell activating receptor ligand expression in lymphangioleiomyomatosis is associated with lung function decline.
- Exosomal miR-940 maintains SRC-mediated oncogenic activity in cancer cells: a possible role for exosomal disposal of tumor suppressor miRNAs
- NKG2D and its ligands in cancer
- HIV-1 targets L-selectin for adhesion and induces its shedding for viral release
- Phosphoproteins Involved in the Inhibition of Apoptosis and in Cell Survival in the Leiomyoma
- Eight immune-related genes predict survival outcomes and immune characteristics in breast cancer
- A distinguishing profile of chemokines, cytokines and biomarkers in the saliva of children with Sjögren’s syndrome
- Human NKG2D Ligand Regulation of NK Cell Functions and Metabolism: From Molecular Mechanisms to Therapeutics
- Unleashing the power of immune checkpoints: Post-translational modification of novel molecules and clinical applications.
- Integrated multi-omics analysis of UL16-binding protein 2 as a prognostic and immunotherapy biomarker for colorectal cancer
- Plasma proteomics enhances genetic risk prediction and biological understanding of venous thromboembolism
- ULBP2 CAR-T cells enhance gastric cancer immunotherapy by inhibiting CAF activation
- Insights into ectodomain shedding as a novel target in natural killer cell-based immunotherapy for cancer
Related papers
- Tumorigenicity of adenovirus-transformed cells and their sensitivity to tumor necrosis factor alpha and NK/LAK cell cytolysis.
- Augmentation of the Susceptibility of Human Leukemia to Lymphokine-Activated Killer (LAK) Cells by Exposure of the Leukemic Target Cells to Cytotoxic Drugs in Vitro and in Vivo.
- Cytolytic and biochemical properties of cytoplasmic granules of murine lymphokine-activated killer cells.
- Modulation of lymphokine release and cytolytic activities by activating peripheral blood lymphocytes via CD2.
- Natural killer cell immunodeficiency in siblings: defective killing in the absence of natural killer cytotoxic factor activity in natural killer and lymphokine-activated killer cytotoxicities.
- Lymphokine-activated killer (LAK) cells. I. Differential recovery of LAK, natural killer cells, and cytotoxic T lymphocytes after a sublethal dose of cyclophosphamide.
- Possible association of decreased NKG2D expression levels and suppression of the activity of natural killer cells in patients with colorectal cancer